cobas® SARS-CoV-2 (original) (raw)

For in vitro diagnostic use. Others cobas SARS-CoV-2 Liat IVD cobas® SARS-CoV-2 RMD-Liat-SARS-003 Nucleic acid test for use on the cobas® liat system 09 408 592 190 9 408 592 190 09408592190 9408592190 09408592190 KIT COBAS LIAT SARS-COV-2 cobas SARS-CoV-2 00875197006742 Reagents, kits 1 pack 20 tests true The cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System (cobas® SARS-CoV-2) is an automated, real- time reverse transcriptase polymerase chain reaction (RT-PCR) test intended for the rapid in vitro qualitative detection of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in anterior nasal (nasal) and nasopharyngeal swab specimens collected from individuals with signs and symptoms of respiratory tract infection (i.e., symptomatic). Additionally, this test is intended to be used with nasal and nasopharyngeal swab specimens collected from individuals without signs and symptoms suspected of COVID-19 (i.e., asymptomatic). The cobas® SARS-CoV-2 performed on the cobas® Liat® System is intended for use as an aid in the diagnosis of COVID-19 if used in conjunction with other clinical, epidemiologic, and laboratory findings. SARS-CoV-2 RNA is generally detectable in nasal and nasopharyngeal swab specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA. Positive results do not rule out co-infection with other microorganisms. A negative result from an asymptomatic individual is presumptive. Additionally, a negative result obtained with a nasal swab collected from an asymptomatic patient should be followed up by testing at least twice over three days with at least 48 hours between tests. Negative results do not preclude SARS-CoV-2 infection. The results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. This test is intended for prescription use only and can be used in Point-of-Care settings. en The cobas® SARS-CoV-2 assay is performed on the cobas® Liat® Analyzer which automates and integrates sample purification, nucleic acid amplification, and detection of the target sequence in biological samples using real-time RT-PCR assays. The assay targets both the ORF1 a/b non-structural region and structural nucleocapsid protein (N) gene that are unique to SARS-CoV-2. An Internal Process Control (IPC) is also included. The IPC is present to control for adequate processing of the target virus through steps of sample purification, nucleic acid amplification, and to monitor the presence of inhibitors in the RT-PCR processes. en

1. Products
2. cobas® SARS-CoV-2

IVD For in vitro diagnostic use.

Delivering lab-quality results at the point of care

The cobas® SARS-CoV-2 assay uses Nobel Prize-winning PCR technology to detect SARS-CoV-2 in just 20 minutes.

The cobas® SARS-CoV-2 assay is CLIA-waived, requires less than 1 minute of hands-on time and offers broad strain coverage of SARS-CoV-2 variants, providing quick, accurate results to support timely clinical decisions.

When symptoms of the most common respiratory infections can look the same, it may be difficult to quickly and accurately diagnose infection based on signs and symptoms alone. The cobas® SARS-CoV-2 helps streamline testing and enables confident treatment decisions when and where it’s needed the most.

cobas^® SARS-CoV-2 intended use¹

cobas® SARS-CoV-2 intended use1

IVD

The cobas® SARS-CoV-2 nucleic acid test for use on the cobas® liat system (cobas® SARS-CoV-2) is an automated, real-time reverse transcriptase polymerase chain reaction (RT-PCR) test intended for the rapid in vitro qualitative detection of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in anterior nasal (nasal) and nasopharyngeal swab specimens collected from individuals with signs and symptoms of respiratory tract infection (i.e., symptomatic). Additionally, this test is intended to be used with nasal and nasopharyngeal swab specimens collected from individuals without signs and symptoms suspected of COVID-19 (i.e., asymptomatic). The cobas® SARS-CoV-2 performed on the cobas® liat system is intended for use as an aid in the diagnosis of COVID-19 if used in conjunction with other clinical, epidemiologic, and laboratory findings. SARS-CoV-2 RNA is generally detectable in nasal and nasopharyngeal swab specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA. Positive results do not rule out co-infection with other microorganisms. A negative result from an asymptomatic individual is presumptive. Additionally, a negative result obtained with a nasal swab collected from an asymptomatic patient should be followed up by testing at least twice over three days with at least 48 hours between tests. Negative results do not preclude SARS-CoV-2 infection. The results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. This test is intended for prescription use only and can be used in Point-of-Care settings.

Would you like to know more about the cobas® SARS-CoV-2?

Please submit your information in the following form to be contacted by a Roche representative with more details about the cobas®SARS-CoV-2.

Reference

1. cobas® SARS-CoV-2 Package Insert, Pleasanton, CA, Roche Molecular Systems Inc**.**

Overview

Detailed Specifications

Ordering Information

Technical Documents

| | | | | | | - | | | ------ |